Three of every 100 U.S. children suffer amblyopia, the leading cause of preventable monocular vision loss.
A Tool That Turns Any Eye Doctor Into a Pediatric Specialist
The Amblyopia Navigator Decision‑Support Instrument (ANDI) is an open‑access web tool that condenses 147 peer‑reviewed studies into a step‑by‑step algorithm. Developed by the NIH‑funded Pediatric Eye Disease Investigator Group (PEDIG), which boasts over 400 investigators, ANDI translates complex evidence into actionable guidance for clinicians without pediatric eye‑care training.
How ANDI Bridges the Workforce Gap
Workforce studies reveal stark geographic disparities: pediatric optometrists and ophthalmologists cluster in a handful of states, leaving many regions without specialists. ANDI mitigates this by enabling any eye doctor—whether general optometrist, ophthalmologist, or primary‑care provider—to deliver evidence‑based amblyopia care. The tool’s online interface is accessible from any internet‑connected device, and its printable figures serve as quick reference sheets for clinics lacking connectivity.
What the Tool Actually Does
- Diagnosis – Input clinical findings to confirm amblyopia and assess severity.
- Glasses Prescription – Calculate the optimal prescription based on inter‑ocular difference and visual acuity.
- Initial Monitoring – Determine how long to observe improvement with glasses alone, which can suffice for up to one‑third of cases.
- Escalation Pathways – If glasses fail, ANDI walks the clinician through patching (hours per day), atropine drops, or newer digital therapies delivered via games or videos.
- Progress Evaluation – Advise on intensifying treatment, reassessing glasses, or referring to a specialist if progress stalls.
- Follow‑Up & Recurrence – Outline visit schedules and red flags to watch for after treatment completion.
Clinicians can use ANDI at the initial visit or any follow‑up, ensuring consistent, evidence‑based care throughout the amblyopia journey. By democratizing access to specialist knowledge, ANDI has the potential to reduce the 3% of children who miss early intervention and suffer lifelong visual deficits.
The tool is freely available at https://public.jaeb.org/pedig, and its publication in JAMA Ophthalmology (May 7 2026, doi:10.1001/jamaophthalmol.2026.1095) underscores its clinical credibility.
With ANDI, the gap between specialist expertise and everyday eye care narrows, offering a scalable solution to a nationwide public‑health problem.
Source: NIH-supported project expands access to care for children with amblyopia
Domain: nih.gov
Comments load interactively on the live page.